Psoriasis Clinical Trial Tracker — Stay Current on IL-17, IL-23, and TYK2 Innovation

Why psoriasis trial monitoring matters

Psoriasis affects over 8 million Americans and more than 125 million people worldwide, making it one of the most commercially significant indications in dermatology and immunology. The treatment landscape has been transformed over two decades by the sequential approval of TNF inhibitors, IL-12/23 blockers, IL-17 inhibitors, IL-23 p19 inhibitors, and now oral TYK2 inhibitors — with each wave generating intense competitive activity in clinical development.

With hundreds of active psoriasis trials on ClinicalTrials.gov, monitoring new registrations is essential for pharma competitive intelligence, biotech investors, and dermatology researchers. Key signals to track:

• Next-generation IL-17 and IL-23 inhibitors — improved dosing, subtype selectivity, and safety profiles
• Oral TYK2 inhibitor programs following deucravacitinib (Sotyktu) approval — competitors and new mechanisms
• Combination trials exploring biologics with novel co-targets (e.g., IL-17 + IL-36, dual cytokine inhibitors)
• Psoriatic arthritis trials — a large and growing adjacent indication
• Biosimilar trials for established biologics (secukinumab, ixekizumab, adalimumab)
• Biomarker and precision medicine studies identifying responder/non-responder phenotypes
• Long-term extension studies reporting durability and safety data

What we monitor for psoriasis

Our pipeline pulls directly from the ClinicalTrials.gov API every day. For a psoriasis watch profile, you can configure:

• Condition keywords: "psoriasis", "plaque psoriasis", "moderate-to-severe plaque psoriasis", "psoriatic arthritis", "psoriatic disease", "pustular psoriasis", "erythrodermic psoriasis"
• Phase filter: Phase 1 only, Phase 2/3, or all phases
• Sponsor filter: Industry-sponsored only (for competitive intelligence) or all sponsors
• Status filter: Recruiting only, all active studies, or any status

The psoriasis treatment landscape in 2026

IL-17 pathway: established leaders and next-generation challengers

The IL-17 axis remains the dominant target in moderate-to-severe plaque psoriasis. Secukinumab (Cosentyx, Novartis) and ixekizumab (Taltz, Eli Lilly) established IL-17A inhibition as the highest-efficacy standard; bimekizumab (Bimzelx, UCB) advanced the class further by inhibiting both IL-17A and IL-17F, demonstrating superior PASI 100 response rates. The pipeline now includes several next-generation IL-17 inhibitors with extended dosing intervals, subcutaneous auto-injector formulations, and improved immunogenicity profiles, each requiring Phase 2 and Phase 3 trials that are actively registering patients.

IL-23 p19 inhibitors: durability and long-term data

The IL-23 p19 selective inhibitors — guselkumab (Tremfya, J&J), risankizumab (Skyrizi, AbbVie), and tildrakizumab (Ilumya, Sun Pharma) — have differentiated on dosing convenience and long-term durability. Head-to-head and combination trials continue to generate data relevant to treatment sequencing decisions. AbbVie's Skyrizi has expanded aggressively into psoriatic arthritis and Crohn's disease, and monitoring its clinical program provides insight into pipeline prioritization across indications.

TYK2 inhibition: oral convenience enters the high-efficacy tier

Deucravacitinib (Sotyktu, Bristol Myers Squibb), the first approved TYK2 inhibitor, demonstrated PASI 75 rates superior to apremilast with a favorable safety profile relative to JAK inhibitors, given its allosteric mechanism. The approval has spurred a wave of competitive TYK2 inhibitor programs in clinical development, along with combination studies pairing TYK2 inhibition with biologics targeting complementary pathways. Tracking new TYK2 trial registrations is critical for companies and investors watching this emerging oral drug class.

Psoriatic arthritis: a large and underserved adjacent opportunity

Approximately 30% of psoriasis patients develop psoriatic arthritis, and the conditions share overlapping biology while requiring distinct efficacy endpoints. Many Phase 3 programs pursue simultaneous skin and joint indications. Monitoring psoriatic arthritis trials is particularly important for companies developing agents with dual dermatology/rheumatology ambitions, as joint outcomes data increasingly influences payer coverage and prescribing decisions across both indications.

Comorbidities and precision medicine

Psoriasis carries significant comorbidity burden — cardiovascular disease, metabolic syndrome, depression, and inflammatory bowel disease all occur at elevated rates. Clinical trials increasingly incorporate cardiovascular outcome endpoints, metabolic biomarkers, and patient-reported outcomes alongside the traditional PASI score. Biomarker studies seeking to predict biologic response are growing in number as the field moves toward precision prescribing and away from trial-and-error sequencing.

Who uses psoriasis trial monitoring

Pharma and biotech companies

Major players including J&J (Janssen), AbbVie, Novartis, UCB, Eli Lilly, and Bristol Myers Squibb maintain active psoriasis clinical programs and monitor competitor activity closely. BD teams track new Phase 1 and Phase 2 trial registrations to identify emerging mechanisms before data become public. Smaller biotechs building next-generation IL-17, IL-23, or TYK2 programs track the crowded landscape to identify differentiation opportunities and avoid head-to-head competition with incumbent approvals.

Dermatology researchers and academic centers

Academic dermatologists at major medical centers track new trial registrations to identify investigator-initiated trial opportunities, understand the competitive landscape for grant applications, and recruit patients into appropriate studies. Psoriasis is one of the most trial-rich dermatologic conditions, and staying current requires systematic monitoring rather than ad hoc searching.

Oncology and immunology investors

Investors with exposure to immunology assets — particularly companies in the IL-17, IL-23, or JAK/TYK2 spaces — monitor psoriasis trial activity as a leading indicator of clinical development strategy. A new Phase 2 trial registration often precedes a clinical readout or partnership announcement by 12–24 months, providing early competitive intelligence that informs portfolio positioning.

Frequently asked questions

How current is the psoriasis trial data?

Our pipeline fetches from ClinicalTrials.gov every morning. Studies posted or updated in the preceding 24 hours appear in that day's digest.

Can I track psoriasis and psoriatic arthritis separately?

Yes. On the Pro plan ($149/month), you can create multiple search profiles. You might have one profile for plaque psoriasis biologics, another for psoriatic arthritis Phase 3 trials, and another for oral small molecules — each delivering a focused daily digest.

Does this cover international psoriasis trials?

ClinicalTrials.gov includes trials conducted internationally, so yes — global psoriasis trials registered on ClinicalTrials.gov are included. Most major industry-sponsored programs, particularly those with US sites, are registered here, covering trials run in Europe, Asia, and Latin America.

How is this different from ClinicalTrials.gov alerts?

ClinicalTrials.gov offers basic RSS-style alerts without phase filtering, sponsor type filtering, or organized digest formatting. We provide filtered, labeled, and organized alerts — the intelligence layer on top of the raw registry data.

Can I filter for specific drug mechanisms like TYK2 or IL-23?

Yes. You can include specific intervention keywords (e.g., "TYK2 inhibitor", "IL-23", "deucravacitinib") alongside condition keywords to narrow your daily digest to the mechanisms most relevant to your work.